A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus

Trial Profile

A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs LY 3298176 (Primary) ; Dulaglutide
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 28 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 25 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Mar 2017 Planned End Date changed from 1 May 2017 to 15 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top